Kisunla™

Understanding Kisunla™ 

Kisunla™ (donanemab-azbt) is an FDA-approved treatment designed for adults with early symptomatic Alzheimer’s disease (AD), including those at the mild cognitive impairment (MCI) or mild dementia stages. This therapy provides a targeted approach for managing early symptoms of AD, potentially slowing disease progression and improving cognitive function.

How Kisunla™ Works:

• Targets and clears amyloid plaques in the brain, a key driver of Alzheimer’s disease
• Designed for early intervention, offering potential benefits in preserving cognitive function
• Helps slow disease progression in individuals diagnosed with early symptomatic AD

FDA Approval:

• Kisunla™ (donanemab-azbt): Approved on July 2, 2024, for the treatment of early symptomatic Alzheimer’s disease.

For more information, please visit the Kisunla™ patient website and speak with your healthcare provider to determine if Kisunla™ is the right treatment option for you.